A reasonable chance it could cause serious harm or death.
Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test
| Brand name | TYDEMY |
| Generic name | DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 |
| NDC | 68180-904-71 |
| Full product label | Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets 0.451 mg), packaged in 1 blister of 28 tablets each (NDC 68180-904-71) further packaged in a carton of 3 blisters (NDC 68180-904-73), Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by Lupin Limited, Pithampur (M.P.), INDIA |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | USA nationwide. |
| Quantity | 4,179 boxes/_ cartons per box/3 pouches each/28 blister per pouch |
| Recall initiated | 2023-06-23 |
| Report date | 2023-08-09 |
| Recall completed | 2025-01-28 |
| Recall number | D-1081-2023 |
| Classification | Class I |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗